论文部分内容阅读
1.8临床试验研究①心力衰竭恶化:Ⅲ期临床试验,纳入4 133例心力衰竭恶化的患者,除标准治疗外,随机分配,口服托伐普坦30 mg,qd(n=2 072)或安慰药(n=2 061),平均疗程9个月,双重主要终点为全因病死率(优效性和非劣效性)和心血管死亡或因心力衰竭住院(仅优效性);次级终点包括呼吸困
1.8 Clinical Trial Study ① Heart Failure Exacerbation: Phase III trial included 4,133 patients with worsening heart failure who were randomly assigned to receive either tolvastatin 30 mg qd (n = 2072) or placebo (n = 2 061) for an average of 9 months. The primary end points for the double-primary end point were all-cause mortality (superior vs. noninferiority) and cardiovascular death or hospitalization for heart failure (predominance only); secondary end points Including breathing difficulties